Table 1:

Patient and Tumor Characteristics:

Patient Characteristics (at inclusion)		n = 17 (%)
Age median (range)		57 years (33-72)
IQR		52; 63
Male / Female		9 (53%) / 8 (47%)
Race; white / not reported		12 (71%) / 5 (29%)
Ethnicity
Hispanic		1 (6%)
Non-hispanic		13 (76%)
Not reported/refused		3 (18%)
WHO Performance Status; median (range)		1 (0 - 1)
Time since initial diagnosis; median (range)		12 months (7 - 51)
Prior Treatments:
Radiotherapy 60 Gy		17 (100%)
Temozolomide		16 (94%)†
# of prior lines of treatment
1		16 (94%)
2		1 (6%)
Corticosteroid therapy (<6 mg/day)		2 (12%)
Anti-epileptic therapy		12 (71%)
Tumor Characteristics (prior to implant surgery)
Mean largest enhancing tumor diameter (mm)		28.7 (range 20-41)
Tumor location
Left	frontal	1 (6%)
	parietal	4 (24%)
	temporal	1 (6%)
Right	frontal	4 (24%)
	parietal	3 (18%)
	temporal	2 (12%)
	occipital	2 (12%)
Pathology on resected specimen
Glioblastoma (IDH wild-type, sequenced)		17 100%
MGMT gene promoter
methylated/unmethylated		5 / 12 (29 / 71%)
Treatment Characteristics
Number of sonication/chemotherapy cycles		68
Number of patients treated dose levels 1-5		5
Number of patients treated at MTD (dose level 6)		12
# pts receiving ≥ 5 cycles		6 (50%)

^†One patient with an MGMT gene promoter unmethylated tumor was treated on a protocol that omitted TMZ in favor of an investigational agent